Longeveron Launches Contract Manufacturing Services, Potentially Generating $4-5M Annually; Signs First Contract With Secretome Therapeutics At Its State-Of-The-Art GMP Facility
Portfolio Pulse from Benzinga Newsdesk
Longeveron has launched contract manufacturing services, potentially generating $4-5 million annually. The company has signed its first contract with Secretome Therapeutics at its state-of-the-art GMP facility.
June 03, 2024 | 1:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Longeveron has launched contract manufacturing services, potentially generating $4-5 million annually. The company has signed its first contract with Secretome Therapeutics at its state-of-the-art GMP facility.
The launch of contract manufacturing services and the signing of the first contract with Secretome Therapeutics are likely to positively impact Longeveron's revenue stream. The potential annual revenue of $4-5 million is significant for the company.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100